Bajaj Healthcare Limited — Important, 14-11-2024: Updates

Bajaj Healthcare Limited has reported strong financial results for the quarter and half-year, with revenue from operations increasing by 32% year-on-year to ₹1,330.9 million for Q2 FY25. Key highlights include a significant 63% growth in PAT from continuing operations, driven by robust performances across all segments. The Opium Processing segment has emerged as a key growth driver, contributing 10.3% to total revenue, up from 2.0% a year ago. The company has also signed a development agreement for an API with a European partner, indicating strong manufacturing capabilities.

Bajaj Healthcare successfully raised approximately ₹2,050 million through the preferential issue of equity shares and warrants, utilizing the funds to repay ₹1,500 million in working capital loans, thereby strengthening its financial position. The focus on expanding its API and formulation segments aligns with favorable domestic demand, while ongoing efforts to manage discontinued operations are also emphasized. Overall, the company projects a positive outlook as it looks to maintain profitability and propel future growth.